# A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

> **NCT06263959** · PHASE2 · RECRUITING · sponsor: **Fujian Akeylink Biotechnology Co., Ltd.** · enrollment: 45 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** GST-HG131
- **DRUG:** Placebo to match GST-HG131

## Key facts

- **NCT ID:** NCT06263959
- **Lead sponsor:** Fujian Akeylink Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-26
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06263959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06263959, "A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06263959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*